Georges Khoury , Sidsel Dan Hull , Cecilia Høst Ramlau-Hansen , Anne Gaml Sørensen , Karin Sørig Hougaard , Kajsa Ugelvig Petersen , Gunnar Toft , Laura Deen , Jens Peter Bonde , Sandra Søgaard Tøttenborg
{"title":"Ever cannabis use and biomarkers of male fecundity – A study in the Danish National Birth Cohort","authors":"Georges Khoury , Sidsel Dan Hull , Cecilia Høst Ramlau-Hansen , Anne Gaml Sørensen , Karin Sørig Hougaard , Kajsa Ugelvig Petersen , Gunnar Toft , Laura Deen , Jens Peter Bonde , Sandra Søgaard Tøttenborg","doi":"10.1016/j.reprotox.2025.109004","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Reports of low semen quality have led to investigations of potential risk factors, including cannabis use. Cannabis affects the endocannabinoid system, which in part regulates spermatogenesis and hormonal balance, but evidence on its impact on male reproductive health remains inconsistent.</div></div><div><h3>Objective</h3><div>This study examined the associations between ever cannabis use and biomarkers of male fecundity in a large cohort of young Danish men incorporating detailed information on their concurrent health behaviors and potential confounding factors during fetal life, a key limitation of previous studies.</div></div><div><h3>Methods</h3><div>We used data from the Fetal Programming of Semen Quality cohort, a sub cohort of 1058 young men born to women enrolled in the Danish National Birth Cohort. Cannabis use was self-reported via an online questionnaire before a clinical examination. Semen samples were collected and analyzed for volume, concentration, total count, motility, morphology, and DNA fragmentation. Hormone levels were measured from venous blood samples. Testicular volume was self-assessed using a Prader Orchidometer.</div></div><div><h3>Results</h3><div>Among participants included in the analytical sample, 324 (31 %) had never used cannabis and 721 (59 %) had used cannabis at least once. We observed no association between ever cannabis use and male fecundity biomarkers, except for a slight indication of higher follicle-stimulating hormone (FSH) levels among ever cannabis users (8 % [95 % CI: −2, 20]).</div></div><div><h3>Conclusion</h3><div>While we found no associations between ever cannabis use and most biomarkers of fecundity in young men, the higher FSH levels among ever cannabis users could suggest early signs of impaired testicular function. However, this needs to be confirmed in studies with a more comprehensive assessment of cannabis exposure.</div></div>","PeriodicalId":21137,"journal":{"name":"Reproductive toxicology","volume":"137 ","pages":"Article 109004"},"PeriodicalIF":2.8000,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reproductive toxicology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0890623825001753","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"REPRODUCTIVE BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Reports of low semen quality have led to investigations of potential risk factors, including cannabis use. Cannabis affects the endocannabinoid system, which in part regulates spermatogenesis and hormonal balance, but evidence on its impact on male reproductive health remains inconsistent.
Objective
This study examined the associations between ever cannabis use and biomarkers of male fecundity in a large cohort of young Danish men incorporating detailed information on their concurrent health behaviors and potential confounding factors during fetal life, a key limitation of previous studies.
Methods
We used data from the Fetal Programming of Semen Quality cohort, a sub cohort of 1058 young men born to women enrolled in the Danish National Birth Cohort. Cannabis use was self-reported via an online questionnaire before a clinical examination. Semen samples were collected and analyzed for volume, concentration, total count, motility, morphology, and DNA fragmentation. Hormone levels were measured from venous blood samples. Testicular volume was self-assessed using a Prader Orchidometer.
Results
Among participants included in the analytical sample, 324 (31 %) had never used cannabis and 721 (59 %) had used cannabis at least once. We observed no association between ever cannabis use and male fecundity biomarkers, except for a slight indication of higher follicle-stimulating hormone (FSH) levels among ever cannabis users (8 % [95 % CI: −2, 20]).
Conclusion
While we found no associations between ever cannabis use and most biomarkers of fecundity in young men, the higher FSH levels among ever cannabis users could suggest early signs of impaired testicular function. However, this needs to be confirmed in studies with a more comprehensive assessment of cannabis exposure.
期刊介绍:
Drawing from a large number of disciplines, Reproductive Toxicology publishes timely, original research on the influence of chemical and physical agents on reproduction. Written by and for obstetricians, pediatricians, embryologists, teratologists, geneticists, toxicologists, andrologists, and others interested in detecting potential reproductive hazards, the journal is a forum for communication among researchers and practitioners. Articles focus on the application of in vitro, animal and clinical research to the practice of clinical medicine.
All aspects of reproduction are within the scope of Reproductive Toxicology, including the formation and maturation of male and female gametes, sexual function, the events surrounding the fusion of gametes and the development of the fertilized ovum, nourishment and transport of the conceptus within the genital tract, implantation, embryogenesis, intrauterine growth, placentation and placental function, parturition, lactation and neonatal survival. Adverse reproductive effects in males will be considered as significant as adverse effects occurring in females. To provide a balanced presentation of approaches, equal emphasis will be given to clinical and animal or in vitro work. Typical end points that will be studied by contributors include infertility, sexual dysfunction, spontaneous abortion, malformations, abnormal histogenesis, stillbirth, intrauterine growth retardation, prematurity, behavioral abnormalities, and perinatal mortality.